Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
2000 Turkeys
Roads, Travel and Traffic
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Jobs
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
2000 Turkeys
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Jobs
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
Standard & Poors 500
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Eli Lilly
(NY:
LLY
)
1,409.16
-22.51 (-1.57%)
Delayed Quote
Updated: 3:30 PM EST, Nov 17, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eli Lilly
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Where Will Eli Lilly Be in 10 Years? 1 Clue: Its Next Potential Blockbuster Just Beat Ozempic Head-to-Head
↗
November 16, 2026
Eli Lilly’s pipeline is an embarrassment of riches.
Via
The Motley Fool
Better Healthcare ETF: Invesco's PJP vs. Simplify's PINK
↗
November 15, 2026
Concentrated pharma exposure delivered 31% returns over one year, while active healthcare management achieved 18%.
Via
The Motley Fool
Topics
ETFs
Prediction: $10,000 Equally Split Between Eli Lilly and Novo Nordisk Will Be Worth This Much by the End of 2027
↗
November 15, 2026
Hint: It’s not a bad investment idea.
Via
The Motley Fool
Which Healthcare ETF Is the Better Buy: VanEck’s Pharma Fund PPH or iShares’ Biotech Fund IBB?
↗
November 15, 2026
One fund owns the big drugmakers that pay dividends. The other owns the broader biotech field, where stocks swing more. Here is which fits long-term investors.
Via
The Motley Fool
Topics
ETFs
LifeMD: 3 Key Takeaways for Long-Term Investors
↗
November 14, 2026
Lower acquisition costs and flat overhead could let LifeMD keep more of each subscriber's revenue as patient volume grows.
Via
The Motley Fool
Topics
Earnings
Firefly Aerospace vs. Redwire: Which Industrials Stock Is a Better Buy for 2027?
↗
November 14, 2026
Firefly's $1.4 billion backlog and Redwire's 45.8% revenue growth point to very different bets, and the valuation gap may be the deciding factor.
Via
The Motley Fool
Prediction: $10,000 Invested in Viking Therapeutics Before Its Oral Phase 3 Readouts Could Be Worth This Much by 2028
↗
November 13, 2026
Even a small share of the weight loss drug market could lead to a substantial increase in the company's share price.
Via
The Motley Fool
What LifeMD (LFMD) Said on Its Q3 Earnings Call
↗
November 12, 2026
LifeMD (NASDAQ:LFMD) lowered its full-year revenue and adjusted EBITDA outlook after third-quarter sales fell short of its forecast, as the virtual healthcare company cut marketing spending and took...
Via
MarketBeat
Topics
Earnings
Nvidia CEO Jensen Huang Says AI's 'Most Profound Impact' Will Be in Life Sciences -- and Eli Lilly Is Already Building on It
↗
November 12, 2026
The world's largest healthcare company is making shrewd investments in its future.
Via
The Motley Fool
Topics
Artificial Intelligence
More Good News for Eli Lilly Sends the Stock Even Higher
↗
November 12, 2026
Lilly's experimental GLP-1 is effective in treating osteoarthritic knee pain.
Via
The Motley Fool
Hims & Hers Bounced Back 9%, But Its Earnings Reveal a Costly Trade-Off
↗
November 12, 2026
Hims & Hers stock sank after a Q3 earnings and revenue miss, lower EBITDA guidance, subscriber declines, and an expanding FTC lawsuit over privacy and billing practices.
Via
MarketBeat
Topics
Earnings
Lawsuit
JPMorgan Predicted Strong Wegovy Pill Sales (and Was Right). Is Novo Nordisk Stock a Buy Now?
↗
November 11, 2026
Novo Nordisk lived up to expectations for its Wegovy pill in the third quarter, but it still has more work ahead.
Via
The Motley Fool
Eli Lilly Just Raised Its 2026 Sales Forecast to as Much as $92 Billion. But Is Viking Therapeutics the Next Big Obesity Winner?
↗
November 11, 2026
These drugmakers offer very different risk-reward profiles.
Via
The Motley Fool
S&P 500 After-Hours Movers: MNST, RDDT Among Gainers; VEEV, LLY Among Losers in Latest Session
↗
November 11, 2026
Via
Chartmill
Topics
Stocks
Which Is the Better Buy: iShares’ Pharma ETF IHE or First Trust’s Biotech Fund FBT?
↗
November 11, 2026
iShares offers lower fees and smoother returns, while First Trust provides concentrated biotech exposure with higher growth potential.
Via
The Motley Fool
Topics
Derivatives
ETFs
Johnson & Johnson vs. Eli Lilly: Which Healthcare Giant's Stock Is a Better Buy for 2027?
↗
November 11, 2026
Eli Lilly's sales jumped 44.7% last year, while Johnson & Johnson's steadier profile raises a different question for cautious portfolios.
Via
The Motley Fool
My Forever Portfolio: 4 Spectacular Stocks You Can Buy Now and Never Sell
↗
November 11, 2026
It takes a slightly different mindset when you're investing for a longer time horizon.
Via
The Motley Fool
Eli Lilly vs Novo Nordisk: What's the Better GLP-1 Stock to Buy?
↗
November 10, 2026
These stocks have been going in different directions over the past year, but that trend may not necessarily continue.
Via
The Motley Fool
Hims & Hers: 3 Key Takeaways for Long-Term Investors
↗
November 10, 2026
Management is betting that a lighter marketing push now sets Hims & Hers up for the January weight-loss surge, but it's unclear whether lost subscribers will return.
Via
The Motley Fool
Topics
Earnings
This Growth ETF Has Crushed the S&P 500 Since 2004. Here's Why It's Still a Buy.
↗
November 10, 2026
The upside outweighs the inevitable volatility.
Via
The Motley Fool
Topics
ETFs
Stocks
Gilead Sciences Stock Hits a New All-Time High: Is it Still a Good Buy?
↗
November 10, 2026
The healthcare stock has soared past the S&P 500 this year as its results have been strong in recent quarters.
Via
The Motley Fool
Topics
Stocks
Want to Escape the AI Sell-Off? This ETF Offers a Surprising Alternative
↗
November 09, 2026
As tech stocks sell off, the ProShares S&P 500 ex-Technology ETF (SPXT) offers reduced AI exposure, but its mega-cap holdings, light liquidity, and trailing returns temper its appeal.
Via
MarketBeat
Topics
Artificial Intelligence
ETFs
Stocks
Eli Lilly Is Now Worth Nearly 9 Novo Nordisks. Here's How the Gap Got So Wide.
↗
November 09, 2026
The companies are competing in the weight loss drug market.
Via
The Motley Fool
3 Super Growth Stocks to Buy Hand Over Fist If the Stock Market Crashes
↗
November 08, 2026
One of these stocks is up 265% over the past year -- and its shares don't seem wildly overvalued, either.
Via
The Motley Fool
Topics
Economy
Novo Nordisk's Wegovy Pill Has Topped 5 Million Prescriptions. Is the Stock a Buy Now?
↗
November 08, 2026
Novo Nordisk is looking to build a volume-driven business, but the successful launch of the Wegovy pill is just the first step.
Via
The Motley Fool
Forget Lilly and Novo: Pfizer Is Planning a Wave of Phase 3 Obesity Trials
↗
November 07, 2026
Everyone is talking about the GLP-1 battle between Eli Lilly and Novo Nordisk, but Pfizer wants in on the fight, too.
Via
The Motley Fool
Eli Lilly Just Raised Its 2026 Revenue Forecast by $5.5 Billion. Is the Stock Still a Buy?
↗
November 07, 2026
The stock is expensive, but the potential market for GLP-1 drugs is likely much larger than forecast.
Via
The Motley Fool
IYH and XBI: Two Distinct Paths to Investing in Healthcare
↗
November 07, 2026
XBI delivered stronger 1-year returns at 45%, but IYH's diversified portfolio weathered volatility far better, with a maximum drawdown of just 17.9% versus 53.2%.
Via
The Motley Fool
Topics
ETFs
Eli Lilly Is Much More Than a Weight-Loss Drug Company. Here's the Evidence
↗
November 06, 2026
Eli Lilly could thrive even as competition in the weight-loss market intensifies.
Via
The Motley Fool
Hims & Hers Surges On 'Surprising And Inevitable' Deal With Eli Lilly
↗
November 06, 2026
Hims & Hers Health inked a deal with Eli Lilly on Friday to sell the company's obesity drugs.
Via
Investor's Business Daily
< Previous
1
2
3
4
5
6
7
8
9
...
99
100
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at
/week.
Subscribe Today